|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
63,610,000 |
Market
Cap: |
305.33(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.6 - $8.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MeiraGTx Holdings is a clinical stage gene therapy company with six programs in clinical development and a pipeline of preclinical and research programs. Co.'s focus is on three areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases and severe forms of xerostomia. Co.'s product candidates include: AAV-RPE65 for the treatment of retinal dystrophy associated with mutations in the RPE65 gene; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of Leber congenital amaurosis 4; as well as AAV-RDH12 for the treatment of RDH12 Mutation-Associated Retinal Dystrophy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
4,347,826 |
4,353,826 |
Total Buy Value |
$0 |
$0 |
$25,000,000 |
$25,047,440 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
1 |
3 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-04-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
1,372,504 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-03-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
1,373,504 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2024-02-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
13,500 |
840,426 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2024-01-14 |
4 |
D |
$6.36 |
$84,073 |
D/D |
(13,219) |
853,926 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
867,145 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2024-01-14 |
4 |
D |
$6.36 |
$93,848 |
D/D |
(14,756) |
89,724 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
104,480 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-14 |
4 |
D |
$6.36 |
$70,997 |
D/D |
(11,163) |
564,329 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,750 |
575,492 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-01-14 |
4 |
D |
$6.36 |
$100,889 |
D/D |
(15,863) |
1,375,504 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
1,391,367 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2024-01-14 |
4 |
D |
$6.36 |
$16,816 |
D/D |
(2,644) |
15,137 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
17,781 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-08 |
4 |
D |
$6.63 |
$124,644 |
D/D |
(18,800) |
551,742 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
570,542 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-01-08 |
4 |
D |
$6.63 |
$170,902 |
D/D |
(25,777) |
1,361,367 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
48,750 |
1,387,144 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2024-01-08 |
4 |
D |
$6.63 |
$131,466 |
D/D |
(19,829) |
842,145 |
|
- |
|
Giroux Richard |
CFO & COO |
|
2024-01-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
861,974 |
|
- |
|
Zeldin Robert K |
CHIEF MEDICAL OFFICER |
|
2024-01-07 |
4/A |
D |
$6.30 |
$86,770 |
D/D |
(13,773) |
71,714 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2024-01-07 |
4 |
D |
$6.30 |
$49,965 |
D/D |
(7,931) |
12,781 |
|
- |
|
Wollin Robert J |
GENERAL COUNSEL AND SECRETARY |
|
2024-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
20,712 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-07 |
4 |
D |
$6.30 |
$222,075 |
D/D |
(35,250) |
530,542 |
|
- |
|
Naylor Stuart |
CHIEF DEV. OFFICER |
|
2024-01-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
75,000 |
565,792 |
|
- |
|
Forbes Alexandria |
PRESIDENT & CEO |
|
2024-01-07 |
4 |
D |
$6.30 |
$416,399 |
D/D |
(66,095) |
1,338,394 |
|
- |
|
130 Records found
|
|
Page 1 of 6 |
|
|